117 related articles for article (PubMed ID: 1995903)
1. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues.
Cushman M; Nagarathnam D; Burg DL; Geahlen RL
J Med Chem; 1991 Feb; 34(2):798-806. PubMed ID: 1995903
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of hydroxylated flavones and related compounds as potential inhibitors of the protein-tyrosine kinase p56lck.
Cushman M; Nagarathnam D; Geahlen RL
J Nat Prod; 1991; 54(5):1345-52. PubMed ID: 1800636
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biochemical evaluation of a series of aminoflavones as potential inhibitors of protein-tyrosine kinases p56lck, EGFr, and p60v-src.
Cushman M; Zhu H; Geahlen RL; Kraker AJ
J Med Chem; 1994 Sep; 37(20):3353-62. PubMed ID: 7932563
[TBL] [Abstract][Full Text] [Related]
4. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition.
Agullo G; Gamet-Payrastre L; Manenti S; Viala C; Rémésy C; Chap H; Payrastre B
Biochem Pharmacol; 1997 Jun; 53(11):1649-57. PubMed ID: 9264317
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases.
Hagiwara M; Inoue S; Tanaka T; Nunoki K; Ito M; Hidaka H
Biochem Pharmacol; 1988 Aug; 37(15):2987-92. PubMed ID: 3164998
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases.
Cunningham BD; Threadgill MD; Groundwater PW; Dale IL; Hickman JA
Anticancer Drug Des; 1992 Oct; 7(5):365-84. PubMed ID: 1388629
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds.
Geahlen RL; Koonchanok NM; McLaughlin JL; Pratt DE
J Nat Prod; 1989; 52(5):982-6. PubMed ID: 2607357
[TBL] [Abstract][Full Text] [Related]
8. Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56lck.
Burke TR; Lim B; Marquez VE; Li ZH; Bolen JB; Stefanova I; Horak ID
J Med Chem; 1993 Feb; 36(4):425-32. PubMed ID: 8474097
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol.
Thakkar K; Geahlen RL; Cushman M
J Med Chem; 1993 Oct; 36(20):2950-5. PubMed ID: 8411012
[TBL] [Abstract][Full Text] [Related]
10. Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin.
Stevens MF; McCall CJ; Lelieveld P; Alexander P; Richter A; Davies DE
J Med Chem; 1994 May; 37(11):1689-95. PubMed ID: 8201603
[TBL] [Abstract][Full Text] [Related]
11. QSAR of aromatic substances: protein tyrosine kinase inhibitory activity of flavonoid analogues.
Deeb O; Clare BW
Chem Biol Drug Des; 2007 Nov; 70(5):437-49. PubMed ID: 17927721
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and inhibitory activities on platelet aggregation of some flavonoid analogues.
Göker H; Tunçbilek M; Leoncini G; Buzzi E; Mazzei M; Rolland Y; Ertan R
Arzneimittelforschung; 1995 Feb; 45(2):150-5. PubMed ID: 7710437
[TBL] [Abstract][Full Text] [Related]
13. Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity.
Faltynek CR; Schroeder J; Mauvais P; Miller D; Wang S; Murphy D; Lehr R; Kelley M; Maycock A; Michne W
Biochemistry; 1995 Sep; 34(38):12404-10. PubMed ID: 7547985
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
15. Quantitative structure-activity relationship of flavonoid analogues. 3. Inhibition of p56lck protein tyrosine kinase.
Oblak M; Randic M; Solmajer T
J Chem Inf Comput Sci; 2000; 40(4):994-1001. PubMed ID: 10955529
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
17. Analysis of styryl-based inhibitors of the lymphocyte tyrosine protein kinase p56lck.
Li ZH; Burke TR; Bolen JB
Biochem Biophys Res Commun; 1991 Oct; 180(2):1048-56. PubMed ID: 1659394
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases.
Palmer BD; Rewcastle GW; Thompson AM; Boyd M; Showalter HD; Sercel AD; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1995 Jan; 38(1):58-67. PubMed ID: 7837241
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
Markovits J; Linassier C; Fossé P; Couprie J; Pierre J; Jacquemin-Sablon A; Saucier JM; Le Pecq JB; Larsen AK
Cancer Res; 1989 Sep; 49(18):5111-7. PubMed ID: 2548712
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
